Interestingly, based on current genomic findings, US TCGA-HNSCC patients with primary tumors universally harbor MAPK1 p.E322K mutations, while an Asian primary/recurrent HNSCC cohort showed a wide spectrum of p.E322K/D321N/R135 mutations12. This evidence concerns the gene MAPK1 and head and neck squamous cell carcinoma.